oneCureGEN Co., Ltd., ‘the 1,000th INNOPOLIS Research Institute Spin-off company', was established in July 2020
through the combining the anticancer drug development technology of KRIBB (Korea Research Institute of Bioscience and Biotechnology)
and the drug delivery technology of iCureBNP Co., Ltd.
Based on the mission to develop innovative drugs to ‘overcome cancers,
we launched the challenge of developing novel target-based global anticancer drugs.
Currently, we are developing companion diagnostic anticancer drugs with high efficiency and fewer side effects through the discovery and verification of biomarkers.
In particular, we focus on developing novel anticancer drugs to meet the unmet needs of patients with intractable and rare cancers.
To this end, we build platform technologies through technological innovation with creativity and a spirit of challenge and strive to strengthen competitiveness
for the development of next-generation innovative anticancer drugs through open innovation.
Aiming for 'a strong company full of vitality with the best technology', oneCureGEN Co., Ltd. will grow into a global company leading the cutting-edge anticancer drug market.
With a spirit of mutual respect and cooperation among employees, we create a sustainable organizational culture and contribute to society as a socially responsible company.
All of our management and employees will do our best to make 'the best company' trusted by customers and shareholders and contribute to promoting mankind’s health.
Thank You
